Overall proportion of industry and non-industry income is: 76.1% industry income vs 23.9% non-industry income. Please find below a list of Industry Partners and related contributions for the financial year 2018:

Industry1 related income (2018)

  Name of company/funder Amount of income2 Percentage of overall budget
  Actelion € 10,000 1,3%
  ADIR-Servier € 10,000 1,3%
  Almirall € 10,000 1,3%
  Biogen € 70,000 9,0%
  Bristol-Myers-Squibb (BMS - formerly Celgene) € 10,820 1,4%
  Icometrix € 5,000 0,6%
  MedDay € 15,000 1,9%
  Merck € 50,000 6,4%
  Novartis € 78,801 10,1%
  Roche € 170,525 21,8%
  Sanofi-Genzyme € 65,000 8,3%
  TEVA € 100,000 12,8%
  Subtotal € 781,583 76.1%
[1] Industry is defined as commercial manufacturers of healthcare products and services, including distributors and wholesalers, etc.
[2] This should reflect the overall funding received from industry, including, e.g. projects, conferences, etc.

2018 EMSP Industry Partners' Logos: Actelion, Almirall, Biogen, Bristol-Myers-Squibb, Icometrix, Medday, Merck, Novartis, Roche, Sanofi-Genzyme, Servier, TEVA

Code of Conduct

On a regular basis, EMSP also collaborates with the European Federation of Pharmaceutical Industries and Associations (EFPIA).

Our approach is transparent and rules-based, as set out in our Code of Conduct.

Industry reports

In order to encourage health literacy and sharing of information, EMSP is supporting a number of important industry-funded deliverables. Find a few examples below:

  • The State of MS Report – an international survey on improving physician-patient dialogue about multiple sclerosis. A Biogen initiative. Find the 2016 State of MS update report here.

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Phasellus eros tortor, molestie in ligula quis, condimentum iaculis metus. Suspendisse lacus lacus, auctor sed nisi ac, bibendum ultrices tellus. Suspendisse quis enim ut arcu mattis accumsan sed id lorem. Ut finibus orci dolor, ac sodales diam tincidunt in.